Vilicom and Virgin Media O2 launch commercial Neutral Host In-Building (NHIB) site
Vilicom are extending Virgin Media O2’s 4G mobile coverage to businesses and its subscribers with…
Month: August 2021
Ultimovacs ASA: Second Quarter 2021 Result Presentation
OSLO, Norway, Aug. 20, 2021 (GLOBE NEWSWIRE) — Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical…
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ
LONDON and NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq:…
Ultimovacs ASA: Second quarter 2021 result presentation
Oslo, 20 August 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune…
Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative…
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for…
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern
Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in…
AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
–Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for…
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative…
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response;…
Kane Biotech to Release Second Quarter 2021 Financial Results on August 26 – Conference Call to Follow
WINNIPEG, Manitoba, Aug. 19, 2021 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
Covis Pharma Announces FDA’s Decision to Grant Public Hearing for Only FDA-Approved Treatment to Reduce Preterm Birth in Indicated Patients
ZUG, Switzerland, Aug. 19, 2021 (GLOBE NEWSWIRE) — Covis Group S.à r.l. (“Covis”) announced today that…
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
PRESS RELEASE NEW DATA REVEAL THE DELETERIOUS ROLE OF ACTIVATED MAST CELLS ON MOTOR NEURONS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND THE…
Avicanna Announces Closing of Secured Debt Financing
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES….
Rafarma Enters Negotiations With Leading Global Producer of Precious Metals to Localize Production of Platinum-Based Cancer Drugs
Nicosia, Cyprus, Aug. 19, 2021 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and one of…
22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors
Anthony Johnson Anthony Johnson – Board of Directors Visionary in the Fields of Biotechnology and Genomics…
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) — Scilex Holding Company (SCILEX), a subsidiary…
Heat Biologics Announces New Additions to Biothreat Advisory Board
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert…
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Company announcement – No. 52 / 2021 Zealand Pharma Announces First Patient Dosed in EASE-SBS…
Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”)…